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Abstract 
Small cell carcinoma of the ovary of the hypercalcemic type (SCCOHT) is a very rare tumor 
type that mainly affects young women. We report a 21-year old woman with SCCOHT. The 
patient initially presented with stage T3AN1MX disease and treated with surgery. The patient 
then received 8 cycles of multi-agent chemotherapy including cisplatin, bleomycin, cyclo-
phosphamide, doxorubicin, and etoposide. Upon relapse, the patient underwent total ab-
dominal  hysterectomy,  followed  by  chemotherapy  with  gemcitabine.  The  patient  subse-
quently  received  radiation  therapy  and  chemotherapy  with  bevacizumab,  irinotecan  and 
docetaxel. She passed away approximately 5 months after the second surgery and with her 
prior permission an immediate autopsy was performed. We examined the gene expression 
and copy number profiles of the tumor tissue samples obtained from the autopsy and com-
pared them to normal ovary tissues. Our results indicated that although this tumor did not 
harbor chromosomal abnormalities nor gene copy number changes, there were significant 
gene expression changes in a number of genes/pathways. More than 5,000 genes showed 
significant  differential  expression  in  the  tumor  when compared  to  normal ovary  tissue. 
Pathway  enrichment  analysis  further  identified  several  pathways/processes  including  the 
Vitamin D receptor signaling and the hedgehog signaling pathways to be significantly dysreg-
ulated. The gene expression profiling also suggests a number of agents such as pazopanib, 
bortezomib, 5-azacytidine, and PARP inhibitors as treatment options to possibly explore in 
future trials against this disease. 
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Introduction 
Small cell carcinoma of the ovary of the hyper-
calcemic type (SCCOHT) is a rare highly aggressive 
neoplasm  that  almost  exclusively  affects  young 
women. The tumor was first reported in 1979 by R. E. 
Scully as a distinct small cell ovarian tumor with un-
known derivation [1]. Several cases have since been 
reported in the literature with the largest series con-
sisting of 150 patients where it was observed that the 
mean age at diagnosis is 24 years and that approxi-
mately  two  thirds  of  patients  present  with  hyper-
calcemia. [2]  
Although SCCOHT is rare, it is the most com-
mon  ovarian  neoplasm  of  the  many  potential  neo-
plasms composed of small round cells in women un-
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der 40. [3, 4] As it can be hard to distinguish between 
the types of uncommon small cell ovarian neoplasms, 
several  reports  and  reviews  describing  the  distin-
guishing  clinical  and  histopathological  features  of 
these tumors have been written. [3-6] 
Despite the number of treatment modalities in-
vestigated, longer term  survival with SCCOHT  still 
occurs  infrequently,  as  any  response  to  these  treat-
ments  appears  to  be  short  lived.  [7-11]  A  VPCBAE 
(vinblastine, cisplatin, cyclophosphamide, bleomycin, 
adriamycin, and etoposide) regimen appears to be the 
preferred treatment in most centers despite its high 
toxicity. [8, 12, 13] Clearly, better therapeutic options 
are needed to fight this disease. 
There are an increasing number of examples of 
tumors  where  molecular  profiling  has  been  able  to 
identify a context of vulnerability that has allowed a 
therapeutic chance where not too long ago they would 
have been considered not very treatable or untreata-
ble. The most commonly cited example is the use of 
imatinib  in  targeting  BCR-ABL  in  Chronic  mye-
logenous leukemia. Another, more recent, example is 
the targeting of aberrant hedgehog signaling in basal 
cell carcinoma [14, 15]. To our knowledge, little work 
has been done to uncover the molecular determinants 
of SCCOHT.  
Herein  we  present  a  study  of  a  patient’s 
SCCOHT. The possibility that a better molecular un-
derstanding of SCCOHT might lead to less toxic and 
more effective therapies, drove us to molecularly pro-
file this tumor and make this information available to 
other translational investigators who have this same 
goal.  
Materials and Methods 
Human tissues 
With the patient’s permission, fresh frozen small 
cell ovarian tumor tissue was obtained via an autopsy 
performed immediately after death. A portion of the 
tumor tissue was fixed with formalin and embedded 
in  paraffin.  Standard  hematoxylin  and  eosin  (H&E) 
staining  was  performed  on  the  paraffin  embedded 
tissue  section  using  a  BondMax  autostainer  (Leica 
Microsystems,  Buffalo  Grove,  IL).  Normal  ovarian 
RNA  was  obtained  through  BioChain  Institute,  Inc 
(Hayward, CA).  
RNA Isolation 
Total RNA from the tumor tissues was extracted 
using TRIzol (Invitrogen, Carlsbad, CA), followed by 
isolation  using  RNeasy  mini  kit  (Qiagen,  Valencia, 
CA). Total RNA from cell pellets was isolated using 
the NucleoSpin® RNA II isolation kit (BD Biosciences, 
Palo Alta, CA). The RNA samples were then used in 
the microarray experiments. 
Oligonucleotide Microarrays and Analysis 
Total RNA (500 ng) was amplified and labeled 
with Cy3 or Cy5 dye using an Agilent (Palo Alto, CA) 
fluorescent linear amplification kit. Labeled amplified 
RNAs  were  fragmented  and  hybridized  on  Agilent 
Human 1A(V2) Oligo Microarray slides using an Ag-
ilent  in  situ  hybridization  kit.  Slides  were  scanned 
using an Agilent G2505B scanner, and Agilent feature 
extraction software (v8.1) was used to calculate nor-
malized signal intensity. Following feature extraction, 
files were opened up in excel and sorting was per-
formed as follows: median normalized intensity val-
ues for each probe were calculated, intensity values 
less than 0.25 (median = 1) were changed to 0.25 to 
prevent transcripts expressed at low levels as being 
identified as differentially regulated, expression ratios 
were calculated by dividing the signal intensity of the 
tumor  by  the  signal  intensity  of  obtained  from  the 
normal ovarian RNA. Array analysis comparing the 
SCCOHT tumor to normal ovarian RNA was done in 
duplicates  with  dye-swab  (For  the  first  array  RNA 
from  the  normal  ovary  was  labeled  with  Cy3  and 
RNA from the tumor tissue was labeled with Cy5; for 
the second array RNA from the tumor tissue was la-
beled Cy3 and RNA from the normal ovary was la-
beled Cy5). Expression ratios from the 2 arrays were 
averaged for a final expression ratio.  
Pathway Enrichment Analysis 
To identify regulatory pathways/networks that 
differentiate  the  tumor  from  the  normal  ovary,  we 
analyzed the differentially expressed genes between 
the tumor and normal ovary samples for relative en-
richment of certain categories from several functional 
ontologies in MetaCore™ (Thomson Reuters v. 6.8), 
including  GO  (gene  ontology),  network  processes, 
canonical pathway maps, and disease networks. The 
MetaCore™ database is a commercially available re-
source  containing  over  200,000  protein-protein  and 
protein-small  molecule  interactions  manually  ex-
tracted from the literature by a group of experts [16]. 
To rank the results we calculated the p-values of each 
identified pathway/network using formula described 
by Nikolsky and colleagues  [17]. The p-value is es-
sentially the probability of a particular mapping aris-
ing by chance given the number of genes in the set 
relative to all genes on maps/processes, genes on a 
particular map/processes, and genes in the analyzed 
experiment  [17].  A  pathway  or  network  with  a 
p-value  of  0.01  or  lower  was  considered  as  signifi-
cantly dysregulated in the tumor.  Journal of Cancer 2012, 3 
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Figure 1. H&E staining of the tumor shows the characteristics of a small cell carcinoma of the ovary. 
 
Results and Discussion 
Case Report 
A 21-year-old- woman was in good health when 
presented  with  a  one-month  history  of  abdominal 
cramping and mild low back pain, fatigue and some 
abdominal  bloating  in  July,  2006.  This  prompted 
work-up  which  included  an  ultrasound  showing  a 
cyst. CT scan confirmed that and in July of 2006 she 
underwent exploratory laparotomy with left salpin-
go-oophorectomy,  omentectomy,  radical  tumor 
debulking and appendectomy. Initial pathology was 
consistent with a 12 cm left ovarian mass small cell 
sub-type  (Figure  1).  Vascular  space  invasion  was 
present. Tumor involved the left pelvic peritoneum, 
the posterior cul-de-sac, the right bladder, peritone-
um, the left external iliac node, left periaortic lymph 
node, left super renal lymph node. She was confirmed 
to be pathologic stage T3AN1MX. CAT scans at base-
line  showed  pulmonary  nodules  of  unclear  signifi-
cance. Initial treatment included multi-agent chemo-
therapy with cisplatin, bleomycin, cyclophosphamide, 
doxorubicin,  and  etoposide.  The  patient  received  a 
total of eight cycles in a period of five and one-half 
months. The patient had dramatic drop in her serum 
CA-125 level during this chemotherapy regimen from 
243U/ml post-surgery to <30U/ml two months after 
treatment and to 7U/ml at the completion of chemo-
therapy. A routine PET/CT one month after the com-
pletion of therapy showed new uptake within the left 
external iliac lymph node as well as uptake within the 
right cul-de-sac as well as area near the rectum. As a 
result the patient underwent total abdominal hyster-
ectomy with multiple lymph node samplings which 
were  then  sent  for  molecular  profiling.  Molecular 
profiling revealed multiple targets that suggest that 
single  agent  gemcitabine  would  be  optimal.  Patient 
was then initiated with gemcitabine as a single agent 
with the standard 1,000mg/m2 dose for three weeks 
in a row with one week off. After one month of ther-
apy  she  began  to  experience  pelvic  discomfort.  Im-
aging showed growth of mass in the cul-de-sac as well 
as growth in the left external iliac pelvic lymph nodes. 
Due to pain the patient was seen by a radiation on-
cologist and received radiation to both areas within 
the pelvis and the pelvic lymph node. Once the pa-
tient had completed the radiation and had a full he-
matologic  recovery  therapy  was  initiated  with  both 
irinotecan and bevacizumab based upon the previous 
molecular profiling results with the intent to repeat 
imaging  one  month  after  she  started  the  therapy. 
Unfortunately, due to some hematuria, bevacizumab 
was  unable  to  be  initially  added.  As  part  of  the 
work-up  for  hematuria  patient  was  found  to  have 
bilateral hydronephrosis with renal insufficiency ul-
timately requiring bilateral nephrostomy tubes. Once 
the nephrostomy tubes had been added she was then 
re-started  on  bevacizumab  in  combination  with  iri-
notecan. After that initial treatment CT scans showed 
progression  within  the  liver,  retroperitoneum,  and 
peritoneum.  The  patient  then  underwent  palliative  Journal of Cancer 2012, 3 
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paracentesis which helped her symptomatically. Once 
again her profile was reviewed and docetaxel was felt 
to be an appropriate agent. The patient then went on 
to receive single agent docetaxel but after starting this 
for  approximately  three  weeks,  she  once  again  de-
veloped  intractable  pain  and  was  admitted  to  the 
hospital  where  she  succumbed  to  her  disease.  The 
patient requested that an autopsy be performed after 
her death to try to help others and we followed her 
request. 
Analysis of Gene Copy Number 
Many malignant tumors and in particular poorly 
differentiated,  highly  aggressive  ones  are  character-
ized in almost all instances by an unstable karyotype 
leading  to  large-scale  chromosomal  abnormalities. 
However,  several  reports  using  multiple  methods 
have  shown  that  SCCOHT  tumors  are  essentially 
diploid  [2,  18-20].  Chromosomal  aberrations  were 
investigated  in  one  study  by  comparative  genomic 
hybridization  (CGH)  for  19  SCCOHT  tumors.  All 
tumors had diploid DNA histograms, and repeatedly 
performed  CGH  analyses  did  not  reveal  any  chro-
mosomal  aberration  [21].  Likewise,  the  SCCOHT 
sample from our patient in this study was examined 
for an unstable karyotype by flow cytometry and by 
Agilent 244k aCGH (data not shown). In agreement 
with the previously reported findings, this tumor was 
diploid, and we were unable to detect any changes in 
chromosomal or gene copy number. Although aCGH 
may miss some minor changes it is intriguing that one 
of  the  most  lethal  gynecological  malignancies  does 
not appear to have significant chromosomal or gene 
copy abnormalities. 
Analysis of Gene Expression 
Global analysis of gene expression is a way to 
characterize  tumors  and  find  potentially  disrupted 
pathways that might be able to be used in rationaliz-
ing better therapeutic targeting. Microarray analysis 
was used to compare the gene expression of this tu-
mor  to  that  of  normal  ovarian  RNA.  Based  on  the 
p-values calculated by the Agilent Feature Extraction 
software for the logarithm ratios of tumor vs. normal 
tissues  (LogRatio  Pvalue),  we  identified  a  total  of 
5,282 genes that showed significantly differential ex-
pression  (LogRatio  Pvalue  <0.001)  between  the 
SCCOHT and normal ovary samples. Among them, 
2,469 genes were up-regulated in the tumor (expres-
sion ratios of tumor vs. normal tissue ranging from 1.6 
to  561)  and  2,813  genes  were  down-regulated  (ex-
pression ratios ranging from 0.6 to 0.004) (Additional 
file 1: Supplementary Table S1).  
One  group  of  transcripts  identified  as 
up-regulated in SCCOHT are cancer/testis (CT) anti-
gens. These include MAGEA4, CSAG2, PRAME and 
DDX43. Adult ovarian tissue is usually reported to be 
CT antigen negative, but CT antigen expression has 
been reported in fetal ovary [22]. CT antigens provide 
attractive targets for cancer-specific immunotherapy, 
as  CT  genes  are  expressed  in  some  normal  tissues, 
such as the testis and in some cases placenta. These 
immunologically protected sites lack MHC I expres-
sion and as such, do not present 'self' antigens to T 
cells.  CSAG2,  also  known  as  Taxol- 
resistance-associated gene (TRAG) is a cancer/testis 
antigen  commonly  overexpressed  in  melanoma  cell 
lines  and  malignant  melanoma.  CSAG2  expression 
has been found to be predictive for clinical outcome in 
ovarian carcinoma patients.[23] 
To further characterize the gene expression pat-
terns  of  this  tumor,  we  used  MetaCore  path-
way/network  enrichment  analysis  tool  to  identify 
pathways  and  processes  that  are  most  significantly 
altered  in  the  tumor  compared  to  normal  ovarian 
cells.  We  conducted  enrichment  analysis  of  the  dif-
ferential  expressed  genes  across  four  functional  on-
tologies:  canonical  pathway  maps,  GO  processes, 
GeneGo  process  networks,  and  disease  networks, 
using the hypergeo-metric distribution [24]. The top 
10 pathways and top 10 process networks were iden-
tified as significantly (P value <0.005) altered in the 
tumor  tissue  were  listed  in  Tables  1  and  2,  respec-
tively. 
The top scored pathway maps is the vitamin D 
receptor (VDR) signaling pathway (Figure 2). VDR is 
modestly down-regulated whereas a number of genes 
that are transcriptionally regulated by VDR are highly 
up- or down-regulated. The expression of parathyroid 
hormone  and  parathyroid  hormone-related  proteins 
was not significantly changed. It is therefore not clear 
whether  or  not  the  dysregulation  of  this  particular 
pathway is related to the hypercalcemia of the patient. 
Another  top  scored  pathway  map  is  the  hedgehog 
signaling pathway (Figure 3). The hedgehog pathway 
has been reported to be activated in a number of can-
cers including basal cell carcinoma, medulloblastoma, 
colon, pancreatic, and ovarian cancer. What is inter-
esting in this case is that it is the hedgehog regulated 
transcription factors (Gli1 and Gli2) and their down-
stream effectors are dysregulated while no significant 
change  in  the  expression  of  the  hedgehog  ligands 
were observed. Further studies are needed to confirm 
and  validate  the  dysregulation  of  these  path-
ways/process networks and their roles in SCCOHT 
tumorigenesis and progression.   Journal of Cancer 2012, 3 
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Table 1. Pathways significantly dysregulated in tumor. 
 
Table 2. Biological process networks significantly dysregulated in tumor. 
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Figure 2. The vitamin D receptor pathway. Genes that were differentially expressed in the tumor in both replicates (Array 
#1 and Array #2 in Additional File 1: Supplementary Table S1) were mapped on pathway. The relative expression of the 
genes was visualized by thermometer-like symbols next to the protein icons (Red indicates upregulation, blue indicates 
downregualtion and the height of the bar indicates the level of change relative to normal control). Detailed legends are 
depicted in Additional file 2: Supplementary Figure S1.  Journal of Cancer 2012, 3 
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Figure 3. The hedgehog pathway. Genes that were differentially expressed in the tumor in both replicates (Array #1 and 
Array #2 in Additional File 1: Supplementary Table S1) were mapped on pathway. The gene expression data were repre-
sented in the map as described in Figure 2. 
 
 
Potential Therapeutic Targets Based on Gene 
Expression Data 
To further explore the possibility of using gene 
expression  profiling  to  select  potential  therapeutics 
for this dreadful disease, we did a drug targets en-
richment analysis in which we mapped the differen-
tially  expressed  genes  onto  a  drug-target  database 
that  contain  a  relationship  table  of  drugs  and  their 
known  targets.  As  shown  in  Table  3,  a  total  of  18 
genes  that  significantly  overexpressed  or  underex-
pressed in the tumor have approved or experimental 
targeted therapeutic agents that could be potentially 
explored against the disease. Among the agents, cis-
platin was used in the treatment of the patient. Other 
agents such as pazopanib, bortezomib, 5-azacytidine, 
and PARP inhibitors could be explored in future trials 
against this disease. 
Conclusions 
A case study of a patient with SCCOHT is re-
ported. Due to the low incidence of this disease, as 
well as a lack of information on the molecular profile 
of the disease, we molecularly profiled this patient’s 
tumor sample. Specifically, we saw no chromosomal 
abnormalities by examination with aCGH. However, 
a  number  of  genes  highly  up  and  down  regulated 
compared to normal ovarian RNA were discovered by  Journal of Cancer 2012, 3 
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oligonucleotide microarray. Pathway analyses further 
identified several biological processes and signaling 
pathways that were significantly enriched for genes of 
which expressions were altered in the patient’s tumor. 
Our results combined with previously published as 
well as future molecular characterization of this tu-
mor type could help in the identification and devel-
opment of new targeted therapeutics for the treatment 
of patients with SCCOHT. 
 
Table 3. Molecular targets with available targeted agents identified from expression profiling. 
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